دورية أكاديمية
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
العنوان: | Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. |
---|---|
المؤلفون: | Yadav S; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Jiang F; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Kurkowska S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.; Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, Poland., Saelee R; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Morley A; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Feng F; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Aggarwal R; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Lawhn-Heath C; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Uribe C; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.; Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.; Department of Radiology, San Francisco VA Medical Center, San Francisco, California; and.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. |
المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Jul 01; Vol. 65 (7), pp. 1064-1069. Date of Electronic Publication: 2024 Jul 01. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
مواضيع طبية MeSH: | Radiopharmaceuticals*/therapeutic use , Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/radiotherapy, Humans ; Male ; Aged ; Retrospective Studies ; Middle Aged ; Prostate-Specific Antigen/blood ; Treatment Outcome ; Single Photon Emission Computed Tomography Computed Tomography ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Dipeptides/therapeutic use ; Aged, 80 and over ; Time Factors ; Lutetium ; Glutamate Carboxypeptidase II/metabolism |
مستخلص: | Understanding the relationship between lesion-absorbed dose and tumor response in 177 Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated 50 patients with 335 index lesions undergoing 177 Lu-PSMA-617 RPT, who had dosimetry analysis performed on SPECT/CT at 24 h after cycles 1 and 2. First, we identified the index lesions for each patient and measured the lesion-based absorbed doses. Lesion-based response was calculated after cycle 2. Additionally, PSA50 response (a decline of 50% from baseline PSA) after cycle 2 was also calculated. The respective responses for mean and maximum absorbed doses and prostate-specific membrane antigen (PSMA) volumetric intensity product (VIP-PSMA) at cycles 1 and 2 were termed SPECT (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.) |
فهرسة مساهمة: | Keywords: SPECT/CT; dosimetry; prostate cancer; radiopharmaceutical therapy; response to RPT; theranostics |
المشرفين على المادة: | 0 (Radiopharmaceuticals) EC 3.4.21.77 (Prostate-Specific Antigen) 0 (Heterocyclic Compounds, 1-Ring) 0 (Dipeptides) 0 (Pluvicto) 5H0DOZ21UJ (Lutetium) EC 3.4.17.21 (Glutamate Carboxypeptidase II) |
تواريخ الأحداث: | Date Created: 20240509 Date Completed: 20240701 Latest Revision: 20240708 |
رمز التحديث: | 20240709 |
DOI: | 10.2967/jnumed.123.267208 |
PMID: | 38724282 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!